Information:
Error:
ID
34226
Description
The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion; ODM derived from: https://clinicaltrials.gov/show/NCT01655524
Link
https://clinicaltrials.gov/show/NCT01655524
Keywords
Versions (1)
- 1/15/19 1/15/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 15, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Coronary Artery Disease NCT01655524
Eligibility Coronary Artery Disease NCT01655524
- StudyEvent: Eligibility
Similar models
Eligibility Coronary Artery Disease NCT01655524
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
patients who have had a qualifying regadenoson stress myocardial perfusion imaging (regadenoson nuclear stress test).
boolean
ID.2
Item
inability to provide an informed consent
boolean
ID.3
Item
known allergic reaction to aminophylline or regadenoson
boolean
ID.4
Item
systolic blood pressure < 90 mmhg
boolean
ID.5
Item
unstable abnormal heart rhythm
boolean
ID.6
Item
pulmonary edema
boolean
ID.7
Item
acute coronary symptoms, myocardial infarction within 48 hours
boolean
ID.8
Item
active dipyridamole, aminophylline or theophylline use
boolean
ID.9
Item
pregnancy
boolean
ID.10
Item
any contraindication to aminophylline according to the drug's package insert: uncontrolled seizure disorder, sepsis with multi-organ failure and liver impairment
boolean